Acetylsalicylic acid (aspirin; ASA) is one of the leading non-steroidal anti-inflammatory drugs (NSAIDs) and is known to act by directly suppressing the activity of cyclooxygenase (COX), the key enzyme catalyzing the biosynthesis of prostaglandins. ASA has wide range of effects and the most well known pharmacological effect is reducing pain or fever.
Skin pigmentation results from melanin synthesis by melanocytes and is caused by exposure to UV radiation. Melanin plays an important role in the prevention of suninduced skin injury, and is a major determinant of skin color. 10, 11) Tyrosinase is a key enzyme in melanin synthesis that catalyzes three different chemical reactions; the hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA), the oxidation of DOPA to DOPAquinone, and the oxidation of 5,6-dihydroxyindole (DHI) to indole-quinone. 12) In the absence of thiols, DOPAquinone changes to DOPAchrome and then to DHI or indole 5,6-quinone 2-carboxylic acid (DHICA). There are two other factors in this melanogenic pathway, one is tyrosinase-related protein-2 (TRP-2; DOPAchrome tautomerase), which catalyzes the conversion of DOPAchrome to DHICA, and the other is TRP-1 (DHICA oxidase) that catalyzes the oxidation of DHICA. [13] [14] [15] [16] [17] Cyclic AMP (cAMP) is a key messenger in melanin synthesis. 18) cAMP inducers such as a-melanocyte stimulating hormone (a-MSH), forskolin, and isobutylmethylxanthine (IBMX) enhance melanogenesis. 19) Investigation of the depigmenting mechanisms and clinical aspects of skin-whitening agents is very important. In addition, increased production and accumulation of melanin leads to many hyperpigmentation disorders such as melasma, postinflammatory pigmentation, solar lentigo, etc., which become prominent with aging. Many chemicals have been demonstrated to show inhibitory effects on melanogenesis through inhibition of the enzymatic activity of tyrosinase, but effects on related gene expression, protein degradation, glycosylation, melanosome transfer, and regulation of cellular signaling are also reported to control melanogenesis (reviewed by Solano et al. 20) and Briganti et al.
21)
). Among these studies the effect of ASA on the pigmentary system is as yet unreported. Therefore, we conducted an investigation on the depigmenting mechanisms of ASA in murine B16 melanoma cells. In this study, we showed that ASA inhibited a-MSH-enhanced melanogenesis in B16 melanoma and this depigmenting mechanism was attributed to the downregulation of tyrosinase expression and/or the increase of tyrosinase degradation.
MATERIALS AND METHODS
Cell Culture B16F1 murine melanoma cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St. Louis, MO, U.S.A.) supplemented with 5% heatinactivated fetal bovine serum (FBS), 50 U/ml penicillin, and 100 mg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 .
Cell Proliferation B16 melanoma was treated with or without chemicals (ASA at 2 mM, arbutin at 2 mM and kojic acid at 200 mM) (Sigma). After treatment for 5-d, cells were harvested using trypsin/EDTA and were counted with a Fuchs-Rosenthal cytometer.
Measurement of Melanin Content Melanin contents were measured as reported by Tsuboi et al. with slight modifications. 22) Cells were treated with test chemicals (ASA at 0.5-2.0 mM, arbutin at 2 mM and kojic acid at 200 mM) in DMEM containing 5% heat inactivated FBS for 5-d. After the treatment, cells were detached by incubation with trypsin/EDTA. Precipitated cells were photographed to evaluate the color, suspended in DMEM for cell counting, and solubilized into boiling 2 M NaOH for 20 min. After cooling to room temperature, the absorbance of the solution was measured at 405 nm for melanin content determination.
Tyrosinase Assay Tyrosinase assay was performed as reported by Masamoto et al. with slight modifications. 23) First, 300 ml of 2.5 mM 3,4-dihydroxyphenylalanine (L-DOPA) solution, 50 ml of dimethyl sulfoxide (DMSO) with or without a sample chemical, and 1.1 ml of 0.1 M phosphate buffer (pH 6.8) were mixed. The mixture was preincubated at 25°C for 10 min before 50 ml of 1380 units/ml tyrosinase in aqueous solution was added, and the reaction was monitored at 475 nm. A control reaction was conducted with DMSO alone. The percentage of activity of tyrosinase was calculated as follows: 100Ϫ[(AϪB)/Aϫ100], where A represents the difference in the absorbance of the control sample between an incubation time of 0.5 and 1.0 min, and B represents the difference in the absorbance of the test sample over the same incubation period. The optical density (O.D.) was measured by a UV spectrophotometer at 475 nm. Kojic acid and arbutin were used as references which are well-known tyrosinase inhibitors. 20, 21) DOPA Staining Assay (Tyrosinase Zymography) The DOPA staining assay was performed as reported by Ichihashi and other authors. [24] [25] [26] B16 melanoma cells were treated with either a-MSH alone or a-MSH plus test chemicals (ASA at 0.5-2.0 mM, arbutin at 2 mM and kojic acid at 200 mM) for 5-d. To identify tyrosinase, samples lysed in 0.1 M sodium phosphate buffer (pH 6.8) containing 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mg/ml aprotinin, and 10 mg/ml leupeptin (but without mercaptoethanol or heating) were resolved by 8% SDS-polyacrylamide gel electrophoresis. Gels containing tyrosinase activity were rinsed in 200 ml of 0.1 M NaH 2 PO 4 (pH 6.8) and equilibrated at room temperature with gentle shaking. After 30 min, the rinse buffer was replaced with fresh buffer. After repeating the rinse procedure once again, the gels were transferred into 200 ml of a staining solution containing the rinse buffer supplemented with 5 mM L-DOPA, and incubated in the dark for 3 h at 37°C. Tyrosinase activity was visualized in the gels as dark melanin-containing bands.
Western Blotting To determine the amount of tyrosinase, Western blotting analysis was performed. B16 melanoma cells were treated with ASA for 5-d. After the treatment, cells were collected and lysed in cell lysis buffer [50 mM Tris-HCl (pH 6.8), 2% SDS, 6% b-mercaptoethanol, 1% glycerol]. Whole cell lysates (5ϫ10 4 cells per well) were separated by 8% SDS-polyacrylamide gel electrophoresis, as reported by Laemmli, and transferred to a nitrocellulose membrane.
27) The membrane were pretreated with 5% skim milk in phosphate-buffered saline with 0.05% Tween 20, and tyrosinase was detected with a rabbit polyclonal anti-tyrosinase antibody (dilution 1 : 1000) that was purchased from Santa Cruz Biotechnology (Santa Cruz), and then incubated with horseradish peroxidase-conjugated secondary antibody at a 1 : 2000 dilution. Bound antibodies were detected using an enhanced chemiluminescence kit (Amersham, Little Chalfont, U.K.) following the manufacturer's instructions. Loading amount of each well was normalized using anti-tubulin antibody.
Statistical Analysis All statistical calculations were carried out using the SPSS software (14.0 for windows) program. Data were analyzed using the Dunnett's test.
RESULTS

The Effect of ASA on Cell Proliferation
To test the effect of ASA on cell proliferation, B16 melanoma cells were incubated with ASA (2 mM), arbutin (2 mM), or kojic acid (200 mM) for 5-d. At these concentrations, both arbutin and kojic acid had no effect on cell proliferation respectively (Fig. 1) . Kojic acid showed strong toxicity at 1 mM (data not shown). Interestingly, 2 mM ASA enhanced cell proliferation to 154% compared with the control culture.
The Effect of ASA on Melanin Production To assess the effect of ASA on melanogenesis, we quantified the melanin content of treated B16 melanoma cells. By treatment with arbutin or kojic acid, the melanin contents of B16 melanoma cells decreased to 44% and 64%, respectively, of the control (Fig. 2) . ASA showed a large inhibitory effect of melanin production (82% at 0.5 mM, 59% at 1 mM and 21% at 2 mM, respectively). Moreover, the colors of the cell pellets changed corresponding to the added chemicals (Fig. 3) . Among the a-MSH stimulated cells, ASA was the most effective in whitening the cell pellet. Treatment with arbutin gave slightly reduction pigmentation, and kojic acid did not show any differences as compared with the control.
DOPA Staining Assay To investigate the mechanism of pigmentation inhibition by ASA, we performed DOPA staining on SDS-PAGE gels (Fig. 4) . Because this assay can directly detect the tyrosinase activity of a protein band separated by electrophoresis in each chemical-treated B16 melanoma line, we can estimate the amount of the active form of tyrosinase generated and removed by de novo synthesis and proteolysis, respectively. B16 melanoma cells were treated with either a-MSH alone or a-MSH plus test substances (arbutin 2 mM, ASA 2 mM, kojic Acid 200 mM) for 5-d. Cell lysates were applied to SDS-PAGE and bands that exhibited tyrosinase activity were detected as described in Materials and Methods.
Tyrosinase activity was very low in non-stimulated cells. On the other hand, a-MSH-stimulated melanoma cells Vol. 31, No. 1 showed high activity in a band whose molecular weight corresponded to tyrosinase protein. Arbutin and kojic acid slightly inhibited a-MSH enhanced tyrosinase activity, and ASA showed the strongest inhibition of tyrosinase activity. ASA inhibited tyrosinase activity dose-dependent manner at concentration range 0.5-2.0 mM.
ASA Did Not Inhibit Tyrosinase Activity Directly in Vitro
We examined the inhibitory effect of ASA on tyrosinase using mushroom tyrosinase. As shown in Fig. 5 , kojic acid clearly showed inhibitory effects on tyrosinase, and 96, 98, and 99% inhibition was observed at concentrations of 1.0, 2.0, and 4.0 mM, respectively. Arbutin showed a slight inhibitory effect in a dose-dependent manner, with 9 and 20% inhibition observed at 2.0 and 4.0 mM, respectively. Surprisingly, ASA did not show an inhibitory effect on tyrosinase activity.
Western Blotting of B16 Melanoma Proteins Treated with ASA To determine whether the result that ASA showed an inhibitory effect on cellular tyrosinase activity was caused by the decreased expression of tyrosinase protein or not, we performed Western blotting against the cell lysate obtained from ASA treated B16 melanoma cells. As shown in Fig. 6 , tyrosinase expression was increased in B16 melanoma cells that were stimulated with a-MSH. On the contrary, ASA decreased a-MSH enhanced tyrosinase expression in a dose-dependent manner.
DISCUSSION
In this study, we report the depigmenting effect of acetylsalicylic acid (ASA) on melanoma cells. ASA inhibited melanin production in B16 melanoma cells that were stimulated by a-MSH. a-MSH acts on cells through the elevation of cAMP concentration resulting in the enhancement of melanin production. a-MSH binds to the melanocortin 1 receptor (MC1R) and activates adenylate cyclase that increases the intracellular cAMP concentration. 28) cAMP activates protein kinase A (PKA), which subsequently increases microphthalmia-associated transcription factor (Mitf) expression. Mitf is a transcription factor that effectively transactivates the expression of tyrosinase and its related genes by binding to their common promoters. 18, 29) ASA caused strong inhibition of melanin production in a-MSH-stimulated B16 melanoma cells. This result is not explained by the toxicity of ASA because ASA did not show any inhibitory effect on cell proliferation. Although previous studies found ASA and other NSAIDs to be promising anticancer agents, 6, 28) ASA did not induce an arrest of cell proliferation on B16 melanoma cells (concentration range at 0.5-2 mM). Because the dose of ASA at the serum level is 1-5 mM in patients with chronic inflammatory diseases, 1, 30) ASA concentration used in this paper (0.5-2.0 mM) is not extremely high dose in comparison with the patients' serum level. On the other hand, actual concentration of arbutin and kojic acid is unknown when used in topical application, but the concentrations used in this paper are same level as used For further investigation of the depigmenting mechanism of ASA, a DOPA staining assay was carried out with lysates of a-MSH-stimulated B16 melanoma cells treated with or without chemicals. In this experiment, we could detect intracellular tyrosinase activity in B16 melanoma cells. Upon incubation with ASA, activity of intracellular tyrosinase decreased. This indicates that there is less amount of active form of tyrosinase in ASA treated cells, because ASA was washed out thoroughly from cells and had little affect on DOPA staining assay. The relationship between melanin content and the color of cell pellet was observed clearly. The more tyrosinase activity was suppressed, the lighter the color of the cell pellet.
We next performed a tyrosinase assay to assess the direct inhibitory effect of ASA on semi-purified tyrosinase. We used arbutin and kojic acid as positive controls. Kojic acid significantly inhibited the catalytic activity of mushroom tyrosinase. Previous reports have shown that kojic acid inhibits tyrosinase extracted from B16 melanoma cells (IC 50 value of 38 mM).
31) Interestingly, ASA did not inhibit mushroom tyrosinase. As we did not check the inhibitory effect on tyrosinase enzyme extracted from B16 melanoma cells, no effect of ASA on mushroom tyrosinase may be due to the difference between species. Considering that many inhibitors show antagonistic effects against the tyrosinase active site, ASA may not inhibit murine derived tyrosinase. Therefore, our result shows the depigmenting effect of ASA was not due to catalytic inhibition of tyrosinase. Moreover, Western blotting analysis of ASA-treated B16 melanoma cell extracts showed that ASA inhibited tyrosinase expression in a dose-dependent manner. Although it is important to elucidate whether ASA can directly inhibit tyrosinase or not, we emphasize the significance that ASA can affect the expression of tyrosinase in living cells.
Recently, some reports demonstrate new depigmenting agents that affect melanogenic gene expression. Kim et al. demonstrated that sphingosine-1-phosphate and C 2 -ceramide inhibit melanin formation via degradation of Microphthalmia-associated transcription factor (Mitf). 32, 33) Mitf plays a crucial role in melanogenesis as the master regulator of tyrosinase, TRP-1, and TRP-2 expression; therefore, down-regulation of Mitf causes hypopigmentation. [34] [35] [36] [37] It seems that the suppression of tyrosinase expression by ASA treatment might be due to down-regulation of Mitf. Previous reports showed that prostaglandins activate the cAMP pathway and increased tyrosinase activity. 38) Sasaki et al. showed topical application of prostaglandin E 2 , and prostaglandin F 2a and its analogs enhanced hair follicle regrowth and melanogenesis in a murine model. 39) We are attempting to investigate the depigmenting effect of other NSAIDs. Among those experiments mefenamic acid inhibited melanogenesis of B16 melanoma (data not shown). If the depigmenting effect of ASA is attributed to the suppression of prostaglandin, other NSAIDs also might be promising depigmenting agents. Further investigation is necessary to elucidate the relationship between depigmenting effect of ASA and characteristics of NSAIDs such as cyclooxygenase inhibitor. If the depigmenting effect of ASA is attributed the suppression of prostaglandin, other NSAIDs also might promising depigmenting agents. Although the basal usage of ASA and other NSAIDs such as analgesic/antipyretic or anti-inflammatory drugs are oral application, most of the whitening agents are used by topical application. It would be necessary to investigate the topical application of ASA derivatives as depigmenting agents, as Vitamin C derivatives are developed for topical application.
In summary, we demonstrate the depigmenting effect of ASA on culture cells. Our results show that ASA can affect tyrosinase expression and that the down-regulation of the cyclic AMP pathway leads to inhibition of melanin synthesis in B16 melanoma cells. Therefore, ASA is a useful inhibitor of melanogenesis and it might be effective in hyperpigmentation disorders and whitening cosmetics. Further studies on the depigmenting mechanism of ASA and other NSAIDs are now underway.
